Active, Not Recruiting
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
- Locations
-
- Research Site Chandler, Arizona, United States
- Research Site Oxnard, California, United States
- Research Site Athens, Georgia, United States
- Research Site Joliet, Illinois, United States